Product Description
Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) used to treat mild-to-moderate pain, and helps to relieve symptoms of arthritis (eg, osteoarthritis or rheumatoid arthritis), such as inflammation, swelling, stiffness, and joint pain. This medicine does not cure arthritis and will only help you as long as you continue to take it. (Sourced from: https://www.mayoclinic.org/drugs-supplements/diclofenac-oral-route/description/drg-20069748)
Mechanisms of Action: COX2 Inhibitor,COX1 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Topical,Transdermal
FDA Designation: *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Novartis
Company Location: BASEL V8 CH 4056
Company CEO: Vasant Narasimhan
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, China, Czech Republic, Denmark, Germany, Greece, Italy, Japan, Poland, United States
Active Clinical Trial Count: 22
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Acute Pain|Cancer Pain|Chronic Pain|Keratosis, Actinic|Low Back Pain|Osteoarthritis, Knee
Phase 2: Musculoskeletal Pain
Phase 1: Healthy Volunteers|Osteoarthritis|Pain Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| OA-01-2022 | P1 |
Recruiting |
Osteoarthritis |
2026-05-01 |
23% |
2025-02-28 |
Primary Completion Date|Primary Endpoints |
| AMZ001 | P3 |
Recruiting |
Osteoarthritis, Knee |
2025-11-01 |
42% |
2025-03-01 |
Primary Endpoints|Start Date|Treatments|Trial Status |
| EPDICTIO75+4F01-2022 | P3 |
Active, not recruiting |
Chronic Pain|Low Back Pain|Acute Pain |
2025-03-31 |
2025-05-02 |
Treatments |
|
| CTR20250470 | P1 |
Completed |
Pain Unspecified|Healthy Volunteers |
2025-03-21 |
2025-05-04 |
Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
| ACTRN12623000273684 | P2 |
Completed |
Musculoskeletal Pain|Osteoarthritis, Knee |
2024-12-03 |
2025-04-20 |
Treatments |
|
| 5%-ige KOH-Lösung vs. Placebo und Diclofenac-Gel zur Behandlung der Aktinischen Keratose | P3 |
Active, not recruiting |
Keratosis, Actinic |
2023-05-15 |
2022-03-13 |
Treatments |
|
| BF-01-2023 | P1 |
Recruiting |
Pain Unspecified |
2026-02-01 |
23% |
2025-03-01 |
Primary Endpoints |
| KP-01-2024 | P2 |
Recruiting |
Osteoarthritis, Knee |
2026-02-01 |
50% |
2025-02-13 |
Primary Endpoints |
| AMZ001-007 | P3 |
Not yet recruiting |
Osteoarthritis, Knee |
2025-09-15 |
2025-05-01 |
Treatments |
|
| AMZ001 | P1 |
Recruiting |
Healthy Volunteers |
2025-04-01 |
69% |
2024-12-13 |
Primary Endpoints|Treatments |
| DITH/VER | P3 |
Recruiting |
Low Back Pain|Acute Pain |
2025-01-02 |
2025-05-02 |
Treatments |
|
| ACTRN12624000341527 | P1 |
Recruiting |
Osteoarthritis, Knee |
2024-07-14 |
2024-08-29 |
Treatments |
|
| KP-01-2022 | P2 |
Completed |
Osteoarthritis, Knee |
2023-12-31 |
50% |
2024-02-29 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
| AMZ001-008 | P1 |
Completed |
Healthy Volunteers |
2023-12-27 |
12% |
2025-04-10 |
Primary Endpoints|Study Completion Date |
| ACTRN12623000261617 | P1 |
Completed |
Musculoskeletal Pain|Osteoarthritis, Knee |
2023-11-17 |
2024-08-29 |
Treatments |
|
| DARE-PDM1 | P1 |
Active, not recruiting |
Pain Unspecified |
2023-09-23 |
12% |
2024-01-12 |
Primary Endpoints |
| ACTRN12622001391763 | P1 |
Completed |
Osteoarthritis |
2023-01-18 |
2024-08-29 |
Treatments |
|
| HP-5000-US-07 | P3 |
Not yet recruiting |
Osteoarthritis, Knee |
2022-08-01 |
15% |
2020-11-30 |
Primary Endpoints|Treatments |
| JapicCTI-205103 | P3 |
Active |
Low Back Pain |
2021-07-31 |
|||
| JapicCTI-205291 | P3 |
Planned |
Low Back Pain |
2020-10-31 |
|||
| Diclofenac 2% in improvement of pain symptoms | P3 |
Active, not recruiting |
Acute Pain |
2017-11-28 |
2022-03-13 |
Treatments |
|
| JapicCTI-173651 | P3 |
Active |
Cancer Pain |
None |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
05/01/2025 |
News Article |
Brightseed and Haleon Announce Strategic Collaboration to Harness AI for Small Molecule Discovery and Human Health Innovation |
|
04/24/2025 |
News Article |
Canada Soccer and Haleon Kickoff Multi-Year Partnership focused on Health and Wellness |
|
03/19/2025 |
News Article |
Virpax Pharmaceuticals Announces Reverse Stock Split |
|
03/18/2025 |
News Article |
Virpax Receives Positive Probudur™ Results for Dose Range Study Moves Towards Next Steps in IND |